Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Express Scripts to add Zepbound to National Preferred Formulary
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
